Comunicado N° 11547
Ref.: Oferta de Compra de
CTI Biopharma Corp.
Código CVSA: 90903
Código ISIN: US12648L6011

Buenos Aires, 1ro de junio de 2023

Sres. Depositantes

Tengo el agrado de dirigirme a Uds. a efectos de hacerles llegar la información que hemos recibido de la Central de Clearing del Exterior The Depositary Trust Company (DTC) sobre el título de la referencia.

Aquellos depositantes que deseen tomar acción al respecto, deberán hacerlo ingresando y autorizando sus instrucciones a través del sistema GIC (Gestión Integral de Custodia – GEDOP Externos) disponible en la siguiente dirección: https://gic.sba.com.ar (Menú Eventos Corporativos Internacionales), no más del 21 de junio de 2023, hasta las 15:00 hs., con el fin de que se proceda a enviar a la mencionada Central las instrucciones correspondientes.

Para mayor información al respecto, adjuntamos el reporte enviado por la Central arriba mencionada (Anexo I).

Ante cualquier consulta sobre el presente evento se podrán comunicar con el Agente de Información designado por el emisor:
D.F. King & Co, Inc.
+1 (212) 269-5550 / +1 (888) 280-6942

Por favor tenga en cuenta que tales títulos serán bloqueados en una cuenta de Caja de Valores hasta la finalización o cancelación del evento.

Cabe destacar que Caja de Valores S.A. trasladará a los señores depositantes los cargos que surjan de las gestiones relacionadas con el presente evento.

CAJA DE VALORES

Señalamos que es de exclusiva responsabilidad de los Depositantes y de los tenedores de los títulos tomar o no acción al respecto; razón por la cual las condiciones del presente no podrán interpretarse como recomendaciones o sugerencias de Caja de Valores S.A. para participar en el evento.

Por cualquier duda o consulta podrán comunicarse con el Area de Eventos Corporativos al 4316-8955.

Sin otro particular los saluda atentamente,

Alejandro Berney

Director Ejecutivo

JCM

jlopez@cajval.sba.com.ar | 00005610

Record Detail Page - 138206754

00005610

CUSIP: 12648L601 | **Ticker:** CTIC | **Issue Description:** CTI BIOPHARMA CORP + | **Issuer Description:** CTI BIOPHARMA CORP + | **Asset Class:** Equity | **Asset Type:** Common Stock | **Event Group:** Reorganizations | **Event Type:** Tender Offer - **Sub Event Type:** Offer to Purchase | **Country of Incorporation:** US | **Processed at DTC:** Yes | **DTC Eligible:** Yes | **Declared Mandatory / Voluntary:** Voluntary | **DTC Mandatory / Voluntary:** Voluntary | **ISO Core M/V:** VOLU | **ISO Event Code:** TEND

Workflow Status: Approved | **XBRL Indicator:** No System Data

Event Details | Comments | Related Events | Security Position | Settlement Activity

Event Details

Event Level

Instruction Messaging Eligibility Flag	Yes	Cancelled Flag	No
Sub Event Type	Offer To Buy (TE)		

DTC Processing

DTC Automated Offer Program	Online		

Other Data

Offeror Name	CLEOPATRA ACQ.	Offeror Type Indicator	Third Party

Options/Payouts

Option 0 - NOAC No Action | Complete | Declared Default Option: Yes | DTC Default Option: No | Supported by DTC: No | Delete

Summary - (Option 000)

Option Type	No Action	Issuer Supported Flag	Yes
Issuer Default Option Flag	Yes	DTC Supported Flag	No
DTC Default Option Flag	No		

Option 1 - CASH Cash | Complete | Declared Default Option: No | DTC Default Option: No | Supported by DTC: Yes | Delete

Full Conditional Flag	No	Agent Approval Required	Y
Agent Accept/Reject Ind	Y	Agent Accept/Reject Date	May-26-2023
Actual Protect Expiration Date	Jun-23-2023	Actual Protect Expiration Time	11:59:59 PM NYC
Allocation Identifier Code	No		

Summary - (Option 001)

Option Type	Cash	Issuer Supported Flag	Yes
Issuer Default Option Flag	No	DTC Supported Flag	Yes
DTC Default Option Flag	No	Contra Cusip	12699AA81
Security Description (Contra CUSIP)	CONTRA CTI BIOPHARMA C +	Withdrawal Privilege Flag	Yes

Dates - (Option 001)

Actual Expiration Date	Jun-23-2023	Actual Expiration Time	11:59:59 PM NYC
Actual Withdrawal Expiration Date	Jun-23-2023	Actual Withdrawal Expiration Time	11:59:59 PM NYC
Actual Cover Protect Expiration Date	Jun-27-2023	Actual Cover Protect Expiration Time	05:00:00 PM NYC
DTC Cover Protect Expiration Date	Jun-27-2023	DTC Cover Protect Expiration Time	05:00:00 PM EDT
DTC Instruction Expiration Date	Jun-23-2023	DTC Instruction Expiration Time	06:00:00 PM EDT
DTC Instruction Start Date	May-31-2023	DTC Withdrawal Expiration Date	Jun-23-2023
DTC Withdrawal Expiration Time	06:00:00 PM EDT		

Other Data - (Option 001)

Proration Flag	No	Odd Lot Priority Flag	No

Option Text - (Option 001)

Option Text	$9.10 NET P/S		

Conditions - (Option 001)

Conditional Tenders Accepted Flag	No		

Agents

Agent Type	Agent ID	Agent Name	Agent Address	Agent Phone Number
Event Agent	00002909	COMPUTERSHARE TRUST CO	250 ROYALL STREET CANTON, MA 02021 US	

Information Agent	00007460	DF KING	48 WALL STREET, 22ND FLOOR NEW YORK, NY 10005 US		**00005610**

Vendor Records

DTCREORG

Raw Data

DTCREORG

jlopez@cajval.sba.com.ar | 00005610

Record Detail Page - 138206754

00005610

CUSIP: 12648L601 | **Ticker:** CTIC | **Issue Description:** CTI BIOPHARMA CORP + | **Issuer Description:** CTI BIOPHARMA CORP + | **Asset Class:** Equity | **Asset Type:** Common Stock | **Event Group:** Reorganizations | **Event Type:** Tender Offer - **Sub Event Type:** Offer to Purchase | **Country of Incorporation:** US | **Processed at DTC:** Yes | **DTC Eligible:** Yes | **Declared Mandatory / Voluntary:** Voluntary | **DTC Mandatory / Voluntary:** Voluntary | **ISO Core M/V:** VOLU | **ISO Event Code:** TEND

Workflow Status: Approved | **XBRL Indicator:** No System Data

Event Details | Comments | Related Events | Security Position | Settlement Activity

Comments

External Comments

Date Added	Comments
May-26-2023 11:54:49 AM	05/26/2023: The Telephone number for the Information Agent is: D.F. King & Co, Inc. Brokers may call: (212) 269-5550. All Others Call: (888) 280-6942. The email address is: ctic@dfking.com * Participants must obtain the Offer to Purchase dated May 25, 2023, and the related Letter of Transmittal, Notice of Guaranteed Delivery, Scheduled 14D-9, for the complete details of the offer. * Upon the terms and conditions set forth in this Offer to Purchase, Cleopatra Acquisition Corp. (the Purchaser), a Delaware corporation and a wholly owned, indirect subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi), a Swedish public limited liability company, are offering to purchase all of the outstanding shares of common stock, par value $0.001 per share, of CTI BioPharma Corp., a Delaware corporation, at a price per Share of $9.10, net to the seller in cash, without interest and subject to any applicable withholding taxes. *
May-26-2023 11:54:49 AM	The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of May 10, 2023, by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (Sobi), Cleopatra Acquisition Corp., a Delaware corporation and a wholly owned, indirect subsidiary of Sobi (the Purchaser) and CTI BioPharma Corp., a Delaware corporation (the Merger Agreement). * As soon as practicable (and in any event within one (1) business day) following the acceptance for payment of the Shares tendered and not properly withdrawn pursuant to the Offer representing at least such number of Shares as shall satisfy the Minimum Condition in accordance with the terms of the Offer and the Merger Agreement (such time of acceptance, the Acceptance Time), and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, the Purchaser will merge with and into CTI BioPharma, with CTI BioPharma continuing as the surviving corporation and as
May-26-2023 11:54:49 AM	a wholly owned, indirect subsidiary of Sobi, pursuant to the provisions of Section 251(h) of the Delaware General Corporation Law (-DGCL-), with no stockholder approval required to consummate the Merger. The closing of the Merger will occur as soon as practicable and, in any event, no later than the first business day after the conditions set forth in the Merger Agreement are satisfied or waived, unless another date is agreed to by the parties. * Each Share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), other than any Shares (i) that are owned by CTI BioPharma or its subsidiary or held in the treasury of CTI BioPharma, or owned by Sobi, the Purchaser or any direct or indirect wholly owned subsidiaries of Sobi or the Purchaser (including, for the avoidance of doubt, any Shares acquired by the Purchaser in the Offer) (the Excluded Shares), or (ii) in respect of which appraisal rights were perfected in accordance
May-26-2023 11:54:49 AM	with Section 262 of the DGCL (the Dissenting Shares), will be automatically converted into the right to receive an amount in cash equal to the Offer Price without interest and subject to any applicable withholding taxes. See Section 17 - -Certain Legal Matters; Regulatory Approvals - Appraisal Rights. * Under no circumstances will interest with respect to the Shares purchased pursuant to the Offer be paid, regardless of any extension of the Offer or delay in making such payment. * Holders of the Shares do not have appraisal rights in connection with the Offer. However, if the Merger is consummated, the holders of Shares immediately prior to the Effective Time who (i) did not tender their Shares Shares in the Offer; (ii) follow the procedures set forth in Section 262 of the DGCL, and (iii) do not thereafter withdraw their demand for appraisal of such Shares or otherwise lose their appraisal rights, in each case in
May-26-2023 11:54:49 AM	accordance with DGCL, will be entitled to a judicial determination of the fair value of their Shares (exclusive of any element of value arising from the accomplishment or expectation of the Merger) and to receive payment of such fair value in cash, together with a fair rate of interest thereon, if any, in lieu of receiving the Offer Price for their Shares. The "fair value" of any Shares could be based upon considerations other than, or in addition to, the price paid in the Offer and the market value of such Shares. Holders of Shares should recognize that the value so determined could be higher or lower than, or the same as, the Offer Price or the consideration payable in the Merger (which is equivalent in amount to the Offer Price). Moreover, we may argue in an appraisal proceeding that, for purposes of such proceeding, the fair value of such Shares is less than such amount. * The Offer and withdrawal rights will expire at one minute after 11:59 P.M.

May-26-2023 11:54:49 AM	Eastern Time on June 23, 2023, unless extended or earlier terminated. * Participants should consult their tax advisor for complete details in reference to withholding taxes. *	00005610
May-26-2023 12:25:27 PM	Participants are advised that DTC's PTOP and PBS Tender platform will be open until the time specified in the CAWeb event record for instruction submissions (and as applicable protects) on the offer-s expiration date. DTC's RTOP and PBS Release Transaction platforms will also be available until 6:00 pm (NYC). Participants wishing to submit instructions after the DTC cutoff time on the offer's expiration date and time must contact the Agent directly via email at CANOTICEOFGUARANTEE@computershare.com. Agent will provide direction on the instruction submission and inventory delivery of the tender securities.	

Displaying 1 to 7 of 7 items

Page 1